Editas Medicine Inc Financials
This page shows Editas Medicine Inc (EDIT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Editas Medicine Inc has an operating margin of -777.2%, meaning the company retains $-777 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -216.6% the prior year.
Editas Medicine Inc's revenue declined 58.6% year-over-year, from $78.1M to $32.3M. This contraction results in a growth score of 0/100.
Editas Medicine Inc carries a low D/E ratio of 0.39, meaning only $0.39 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.75, Editas Medicine Inc holds $3.75 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Editas Medicine Inc generated -$210.3M in operating cash flow, capex of $8.8M consumed most of it, leaving -$219.1M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Editas Medicine Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Editas Medicine Inc generates $0.89 in operating cash flow (-$210.3M OCF vs -$237.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Editas Medicine Inc earns $-118.0 in operating income for every $1 of interest expense (-$251.2M vs $2.1M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Editas Medicine Inc generated $32.3M in revenue in fiscal year 2024. This represents a decrease of 58.6% from the prior year.
Editas Medicine Inc's EBITDA was -$245.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 50.4% from the prior year.
Editas Medicine Inc generated -$219.1M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 60.1% from the prior year.
Editas Medicine Inc reported -$237.1M in net income in fiscal year 2024. This represents a decrease of 54.7% from the prior year.
Editas Medicine Inc earned $-2.88 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 42.6% from the prior year.
Editas Medicine Inc held $131.5M in cash against $52.4M in long-term debt as of fiscal year 2024.
Editas Medicine Inc had 83M shares outstanding in fiscal year 2024. This represents an increase of 1.2% from the prior year.
Editas Medicine Inc's operating margin was -777.2% in fiscal year 2024, reflecting core business profitability. This is down 560.7 percentage points from the prior year.
Editas Medicine Inc's net profit margin was -733.7% in fiscal year 2024, showing the share of revenue converted to profit. This is down 537.6 percentage points from the prior year.
Editas Medicine Inc invested $199.2M in research and development in fiscal year 2024. This represents an increase of 12.2% from the prior year.
Editas Medicine Inc invested $8.8M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 87.0% from the prior year.
EDIT Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'23 | Q3'24 | Q2'24 | Q1'24 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.5M+110.8% | $3.6M-23.2% | $4.7M-92.2% | $60.0M+1025.4% | $5.3M+84.8% | $2.9M-70.7% | $9.9M+50.7% | $6.5M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $19.8M+22.2% | $16.2M-39.2% | $26.6M-61.8% | $69.6M+71.7% | $40.5M+36.0% | $29.8M-21.2% | $37.8M-27.3% | $52.0M |
| SG&A Expenses | $12.3M-4.2% | $12.9M-3.9% | $13.4M-7.5% | $14.5M-3.5% | $15.0M-12.9% | $17.2M-25.2% | $23.0M+27.9% | $18.0M |
| Operating Income | -$24.5M+52.4% | -$51.5M+32.3% | -$76.2M-217.8% | -$24.0M+52.2% | -$50.2M-13.8% | -$44.1M+13.5% | -$51.0M+19.7% | -$63.4M |
| Interest Expense | $2.4M+18.8% | $2.0M-8.8% | $2.2M | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$25.1M+52.8% | -$53.2M+30.0% | -$76.1M-303.1% | -$18.9M+58.1% | -$45.0M-11.7% | -$40.3M+17.8% | -$49.0M+19.3% | -$60.7M |
| EPS (Diluted) | $-0.28+55.6% | $-0.63+31.5% | $-0.92-360.0% | $-0.20+63.6% | $-0.55+1.8% | $-0.56+21.1% | $-0.71+19.3% | $-0.88 |
EDIT Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'23 | Q3'24 | Q2'24 | Q1'24 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $201.8M-4.2% | $210.6M-20.1% | $263.7M-47.2% | $499.2M-1.1% | $504.6M-6.9% | $542.0M+16.8% | $464.1M-9.8% | $514.3M |
| Current Assets | $176.9M-3.2% | $182.8M-18.7% | $224.8M-34.0% | $340.8M-5.0% | $358.6M-18.7% | $441.0M+35.9% | $324.5M-9.1% | $356.8M |
| Cash & Equivalents | $165.6M+19.6% | $138.5M-0.1% | $138.7M+12.2% | $123.7M+49.8% | $82.5M-62.6% | $220.8M+71.1% | $129.0M-8.8% | $141.5M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $188.3M-1.6% | $191.4M-4.9% | $201.2M+34.1% | $150.1M+4.1% | $144.2M+1.5% | $142.0M-3.1% | $146.6M-4.6% | $153.6M |
| Current Liabilities | $61.8M-6.3% | $65.9M-9.8% | $73.1M+15.7% | $63.2M+7.9% | $58.6M+7.5% | $54.5M-4.6% | $57.2M-4.9% | $60.1M |
| Long-Term Debt | $54.1M+4.6% | $51.7M+4.2% | $49.6M | $0 | N/A | N/A | N/A | N/A |
| Total Equity | $13.5M-29.9% | $19.2M-69.3% | $62.4M-82.1% | $349.1M-3.2% | $360.5M-9.9% | $399.9M+26.0% | $317.5M-12.0% | $360.7M |
| Retained Earnings | -$1.6B-1.6% | -$1.6B-3.4% | -$1.5B-25.4% | -$1.2B-1.6% | -$1.2B-3.9% | -$1.2B-3.6% | -$1.1B-4.5% | -$1.1B |
EDIT Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'23 | Q3'24 | Q2'24 | Q1'24 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$30.8M+38.6% | -$50.2M-5.0% | -$47.8M-114.9% | -$22.2M+37.3% | -$35.5M+8.4% | -$38.7M-8.2% | -$35.8M+15.4% | -$42.3M |
| Capital Expenditures | $433K | $0-100.0% | $114K-91.3% | $1.3M+446.9% | $239K-82.1% | $1.3M-27.6% | $1.8M+194.9% | $624K |
| Free Cash Flow | -$31.3M+37.7% | -$50.2M-4.8% | -$47.9M-103.5% | -$23.5M+34.0% | -$35.7M+10.9% | -$40.0M-6.5% | -$37.6M+12.3% | -$42.9M |
| Investing Cash Flow | $39.6M-7.2% | $42.6M-24.4% | $56.4M-10.3% | $62.8M+161.1% | -$102.8M-892.0% | $13.0M-44.2% | $23.3M+184.5% | -$27.5M |
| Financing Cash Flow | $17.2M+131.6% | $7.4M+615.8% | -$1.4M-379.6% | $514K | $0-100.0% | $117.5M | $0-100.0% | $619K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EDIT Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'23 | Q3'24 | Q2'24 | Q1'24 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -325.4%+1115.1pp | -1440.6%+194.5pp | -1635.1%-1595.2pp | -39.9%+900.2pp | -940.1%+587.2pp | -1527.3%-1010.0pp | -517.3%+453.3pp | -970.6% |
| Net Margin | -333.0%+1154.9pp | -1487.8%+145.7pp | -1633.5%-1602.1pp | -31.4%+812.3pp | -843.7%+551.9pp | -1395.6%-897.8pp | -497.8%+431.4pp | -929.1% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -12.4%+12.8pp | -25.3%+3.6pp | -28.9%-25.1pp | -3.8%+5.1pp | -8.9%-1.5pp | -7.4%+3.1pp | -10.6%+1.2pp | -11.8% |
| Current Ratio | 2.86+0.1 | 2.77-0.3 | 3.08-2.3 | 5.39-0.7 | 6.12-2.0 | 8.09+2.4 | 5.68-0.3 | 5.93 |
| Debt-to-Equity | 4.02+1.3 | 2.69+1.9 | 0.79+0.8 | 0.00-0.4 | 0.40+0.0 | 0.36-0.1 | 0.46+0.0 | 0.43 |
| FCF Margin | -414.6%+988.7pp | -1403.3%-374.7pp | -1028.6%-989.4pp | -39.2%+629.8pp | -669.0%+718.0pp | -1387.0%-1005.3pp | -381.8%+274.4pp | -656.2% |
Similar Companies
Frequently Asked Questions
What is Editas Medicine Inc's annual revenue?
Editas Medicine Inc (EDIT) reported $32.3M in total revenue for fiscal year 2024. This represents a -58.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Editas Medicine Inc's revenue growing?
Editas Medicine Inc (EDIT) revenue declined by 58.6% year-over-year, from $78.1M to $32.3M in fiscal year 2024.
Is Editas Medicine Inc profitable?
No, Editas Medicine Inc (EDIT) reported a net income of -$237.1M in fiscal year 2024, with a net profit margin of -733.7%.
What is Editas Medicine Inc's earnings per share (EPS)?
Editas Medicine Inc (EDIT) reported diluted earnings per share of $-2.88 for fiscal year 2024. This represents a -42.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Editas Medicine Inc's EBITDA?
Editas Medicine Inc (EDIT) had EBITDA of -$245.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Editas Medicine Inc have?
As of fiscal year 2024, Editas Medicine Inc (EDIT) had $131.5M in cash and equivalents against $52.4M in long-term debt.
What is Editas Medicine Inc's operating margin?
Editas Medicine Inc (EDIT) had an operating margin of -777.2% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Editas Medicine Inc's net profit margin?
Editas Medicine Inc (EDIT) had a net profit margin of -733.7% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Editas Medicine Inc's free cash flow?
Editas Medicine Inc (EDIT) generated -$219.1M in free cash flow during fiscal year 2024. This represents a -60.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Editas Medicine Inc's operating cash flow?
Editas Medicine Inc (EDIT) generated -$210.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Editas Medicine Inc's total assets?
Editas Medicine Inc (EDIT) had $341.6M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Editas Medicine Inc's capital expenditures?
Editas Medicine Inc (EDIT) invested $8.8M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Editas Medicine Inc spend on research and development?
Editas Medicine Inc (EDIT) invested $199.2M in research and development during fiscal year 2024.
How many shares does Editas Medicine Inc have outstanding?
Editas Medicine Inc (EDIT) had 83M shares outstanding as of fiscal year 2024.
What is Editas Medicine Inc's current ratio?
Editas Medicine Inc (EDIT) had a current ratio of 3.75 as of fiscal year 2024, which is generally considered healthy.
What is Editas Medicine Inc's debt-to-equity ratio?
Editas Medicine Inc (EDIT) had a debt-to-equity ratio of 0.39 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Editas Medicine Inc's return on assets (ROA)?
Editas Medicine Inc (EDIT) had a return on assets of -69.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Editas Medicine Inc's cash runway?
Based on fiscal year 2024 data, Editas Medicine Inc (EDIT) had $131.5M in cash against an annual operating cash burn of $210.3M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Editas Medicine Inc's Piotroski F-Score?
Editas Medicine Inc (EDIT) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Editas Medicine Inc's earnings high quality?
Editas Medicine Inc (EDIT) has an earnings quality ratio of 0.89x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Editas Medicine Inc cover its interest payments?
Editas Medicine Inc (EDIT) has an interest coverage ratio of -118.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Editas Medicine Inc?
Editas Medicine Inc (EDIT) scores 39 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.